Search company, investor...

Predict your next investment

Venture Capital
avalon-ventures.com

Investments

255

Portfolio Exits

58

Funds

12

Partners & Customers

2

About Avalon Ventures

Avalon Ventures is a San Diego-based venture capital fund focusing on seed and early stage companies in life sciences, wireless communications and Web 3.0 digital media, primarily in California and the Northeast.

Headquarters Location

1134 Kline Street

La Jolla, California, 92037,

United States

858-348-2180

Want to inform investors similar to Avalon Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Avalon Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Avalon Ventures in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing Avalon Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Avalon Ventures in 2 CB Insights research briefs, most recently on Jun 9, 2021.

Latest Avalon Ventures News

Enlaza Therapeutics Launches with $61 Million Financing

Dec 19, 2022

December 19, 2022 LA JOLLA, Calif.–( BUSINESS WIRE )– Enlaza Therapeutics , the first covalent biologic platform company, today announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-Lock platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with targeted efficacy and low toxicity. “We’ve combined recent breakthroughs that allow introduction of proprietary unnatural amino acids to protein drugs, which enables specific covalent binding to their target proteins,” said Sergio Duron, Ph.D., CEO of Enlaza Therapeutics. “Our covalent biologic platform is white-space technology, and we are pioneering an entirely new class of biologic therapeutics with the potential for significantly improved efficacy and safety to address numerous indications and disease areas.” “Enlaza has built a highly differentiated therapeutic platform which, for the first time, will enable covalent biologics,” said Jay Lichter, Ph.D., Managing Partner of Avalon Ventures. “The platform provides the opportunity to develop drugs against multiple target classes, offering opportunities across all therapeutic areas.” The War-Lock platform creates highly specific therapeutic warheads that lock onto targets of interest, producing broadly applicable therapeutic candidates with excellent drug-like properties. For example, protein drugs derived from the platform can be modified to incorporate various payloads, creating antibody-drug conjugates (ADCs) or radioligand therapies (RLTs) with specific target tissue delivery, without the need for half-life extension engineering. Enlaza has generated preclinical data for its oncology drug candidates showing fast tumor penetration coupled with high systemic clearance, high tumor retention, and low off-target toxicity. “The breadth of Enlaza’s platform will be transformative across multiple modalities,” said Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners. Marcos Milla, Ph.D., Venture Partner at Samsara BioCapital said, “The Enlaza platform opens the possibility to enhance the therapeutic index of biologic drugs in a way that is not accessible with platforms relying on conventional recombinant technologies. It also offers an opportunity to address hard to target cell surface molecules in a highly specific fashion.” “We are impressed with the in vitro and in vivo data the team has generated and believe that Enlaza can build an industry leading pipeline of important new protein drugs employing its incomparable technological advantage,” said Jamie Topper, M.D., Ph.D., Managing Partner of Frazier Life Sciences. In addition to Dr. Duron, Enlaza’s leadership team includes Sanford (Sandy) Madigan, Ph.D., President and Chief Business Officer, Analeah Heidt, Ph.D., Chief Scientific Officer, and Lei Wang Ph.D., Scientific Advisor and Professor at the University of California, San Francisco (UCSF). The company’s Board of Directors is comprised of Jay Lichter, Ph.D. Avalon Ventures; Jamie Topper, M.D., Ph.D., Frazier Life Sciences, Shelley Chu, M.D., Ph.D., Lightspeed Venture Partners, Marcos Milla, Ph.D., Samsara BioCapital, and Sergio Duron, Ph.D., CEO, Enlaza Therapeutics. Enlaza’s War-Lock platform is based on technologies exclusively licensed from UCSF, negotiated through UCSF’s Innovation Ventures’ Office of Technology Management & Advancement, which leads licensing and business development efforts on behalf of the University, and The Scripps Research Institute. About Enlaza Therapeutics Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics. For more information, please visit www.enlazatx.com .

Avalon Ventures Investments

255 Investments

Avalon Ventures has made 255 investments. Their latest investment was in Enlaza Therapeutics as part of their Seed VC on December 12, 2022.

CBI Logo

Avalon Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/15/2022

Seed VC

Enlaza Therapeutics

$61M

Yes

8

12/2/2022

Seed VC

Arialys

$14.33M

Yes

Avalon Ventures, MPM Capital, and Undisclosed Investors

1

11/15/2022

Series C

Jnana Therapeutics

$107M

No

7

10/7/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

8/18/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/15/2022

12/2/2022

11/15/2022

10/7/2021

8/18/2021

Round

Seed VC

Seed VC

Series C

Series A

Series B

Company

Enlaza Therapeutics

Arialys

Jnana Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$61M

$14.33M

$107M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Avalon Ventures, MPM Capital, and Undisclosed Investors

Sources

8

1

7

10

10

Avalon Ventures Portfolio Exits

58 Portfolio Exits

Avalon Ventures has 58 portfolio exits. Their latest portfolio exit was Kaltura on July 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/21/2021

IPO

$99M

Public

18

6/11/2021

IPO

$99M

Public

1

2/26/2021

Acquired

$99M

10

8/24/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/23/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/21/2021

6/11/2021

2/26/2021

8/24/2020

4/23/2020

Exit

IPO

IPO

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

18

1

10

10

10

Avalon Ventures Fund History

12 Fund Histories

Avalon Ventures has 12 funds, including Avalon Ventures XI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/6/2016

Avalon Ventures XI

Early-Stage Venture Capital

Open

$116.53M

3

8/30/2012

Avalon Ventures X

Early-Stage Venture Capital

Closed

$201.63M

1

8/1/2012

10Th Capital Fund

$201.6M

7/19/2010

Avalon Ventures IX

Subscribe to see more

Subscribe to see more

$99M

10

2/27/2008

Avalon Ventures VIII

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

9/6/2016

8/30/2012

8/1/2012

7/19/2010

2/27/2008

Fund

Avalon Ventures XI

Avalon Ventures X

10Th Capital Fund

Avalon Ventures IX

Avalon Ventures VIII

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Subscribe to see more

Subscribe to see more

Amount

$116.53M

$201.63M

$201.6M

$99M

$99M

Sources

3

1

10

10

Avalon Ventures Partners & Customers

2 Partners and customers

Avalon Ventures has 2 strategic partners and customers. Avalon Ventures recently partnered with GSK on April 4, 2013.

Date

Type

Business Partner

Country

News Snippet

Sources

4/23/2013

Partner

United Kingdom

Avalon Ventures GlaxoSmithKline Launch Sitari Pharm With 10 Million Series A And RD Support

Community of Innovation , founded in 2013 , provides operational support to Sitari Pharmaceuticals , the first company funded through the Avalon-GlaxoSmithKline collaboration , as well as existing Avalon Ventures portfolio companies , Afraxis , Avelas Biosciences , RQx Pharmaceuticals and Sova Pharmaceuticals .

4

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

4/23/2013

Type

Partner

Partner

Business Partner

Country

United Kingdom

United Kingdom

News Snippet

Avalon Ventures GlaxoSmithKline Launch Sitari Pharm With 10 Million Series A And RD Support

Community of Innovation , founded in 2013 , provides operational support to Sitari Pharmaceuticals , the first company funded through the Avalon-GlaxoSmithKline collaboration , as well as existing Avalon Ventures portfolio companies , Afraxis , Avelas Biosciences , RQx Pharmaceuticals and Sova Pharmaceuticals .

Subscribe to see more

Subscribe to see more

Sources

4

10

Avalon Ventures Team

9 Team Members

Avalon Ventures has 9 team members, including current Founder, Managing Partner, Kevin Kinsella.

Name

Work History

Title

Status

Kevin Kinsella

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Kevin Kinsella

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.